The dominant COVID variant circulating right now is XFG, a family of sublineages that together account for roughly 70% of all sequenced cases in the United States. Within that family, XFG.1.1 is the single largest lineage at about 32% of cases, followed by the parent XFG lineage at 13% and XFG.14.1 at 8%. Several other XFG offshoots and a handful of unrelated lineages like PQ.17 and NB.1.8.1 make up the rest.
How XFG Took Over
COVID variants rise to dominance the same way every time: they pick up mutations that let them spread faster or slip past existing immunity. XFG carries changes in the spike protein, the part of the virus that latches onto human cells. Earlier research on closely related variants showed that even one or two spike mutations can meaningfully boost infectivity and help the virus dodge antibodies built up from prior infections or vaccination. That combination of higher infectivity and better immune evasion gives a variant a growth advantage, allowing it to outcompete whatever came before it.
The World Health Organization currently lists XFG as a “variant under monitoring,” one step below a full “variant of interest.” That classification means scientists are watching it closely but haven’t yet flagged unusual severity or a dramatic shift in how the virus behaves. Other lineages under monitoring alongside XFG include KP.3.1.1, NB.1.8.1, and BA.3.2.
Symptoms With Current Strains
The symptom picture hasn’t changed dramatically. COVID still presents with a wide range of severity, from barely noticeable to serious. Symptoms typically appear 2 to 14 days after exposure and can include fever or chills, cough, sore throat, congestion or runny nose, fatigue, muscle aches, headache, shortness of breath, nausea, vomiting, and diarrhea. Loss of taste or smell still occurs but is less common than it was with earlier variants.
Most people experience something that feels like a bad cold or mild flu. The symptoms that should prompt urgent medical attention are the same as before: trouble breathing, persistent chest pain or pressure, new confusion, or an inability to stay awake. Skin, lips, or nail beds turning pale, gray, or blue is another warning sign of oxygen problems.
How Well Vaccines Hold Up
The 2024–2025 updated COVID vaccine still offers meaningful protection, particularly against the worst outcomes, though it doesn’t block infection as effectively as earlier formulations did against their target variants. CDC data from September 2024 through January 2025 found the updated shot was about 33% effective at preventing emergency department or urgent care visits among adults 18 and older. Protection against hospitalization was stronger: 45% to 46% for immunocompetent adults 65 and older, and 40% for immunocompromised adults in the same age group.
Those numbers may sound modest, but they represent real reductions in the chance of ending up in a hospital bed. Vaccine effectiveness tends to be highest in the first few months after a dose, which is why timing your shot before periods of high transmission (typically fall and winter) matters more than chasing a perfect match to whatever variant is circulating.
Treatments Still Work
The antiviral treatment nirmatrelvir/ritonavir (sold as Paxlovid) remains effective against current strains. It targets the virus’s replication machinery rather than the spike protein, so the mutations that help new variants dodge antibodies don’t affect how the drug works. In high-risk patients, Paxlovid reduced the risk of death by 73% in a large NIH study. Some people experience a brief return of symptoms after finishing the five-day course, sometimes called “Paxlovid rebound,” but CDC reviews have found no consistent link between the drug itself and rebound. Symptom rebound can happen with or without treatment.
Do Home Tests Still Detect It?
Yes. Rapid antigen tests are designed to detect a protein found across all known SARS-CoV-2 variants, not just specific lineages, so they continue to work with XFG and its sublineages. That said, antigen tests are inherently less sensitive than the PCR tests used in clinical labs, especially early in an infection before viral levels climb.
If you test negative but have symptoms or a known exposure, the FDA recommends testing again at least 48 hours later. A single negative rapid test doesn’t rule out COVID, but two negatives spaced apart make a false negative much less likely. For the most accurate single result, a PCR test from a lab or clinic remains the gold standard.
What Makes This Wave Different
The shift toward XFG represents a continuation of the pattern that has defined COVID since Omicron arrived in late 2021: new sublineages emerge every few months, each slightly better at reinfecting people who’ve had COVID before. None of the currently circulating variants have shown signs of causing more severe disease than their predecessors. Hospitalizations and deaths remain far below early-pandemic levels, largely because of widespread immunity from both vaccination and prior infection.
The practical takeaway is straightforward. The virus is still circulating and still evolving, but the tools available, vaccines, antivirals, and home tests, continue to work against XFG. Staying current on vaccination, testing when symptomatic, and starting antiviral treatment early if you’re at high risk remain the most effective ways to reduce your chances of a serious outcome.